)
The Ahmedabad-based Torrent Pharmaceuticals has entered into an exclusive licensing agreement with Reliance Life Sciences for marketing three biosimilars in India — Rituximab, Adalimumab and Cetuximab.
Rituximab and Cetuximab cater to the oncology segment and are used in the treatment of various cancers such as leukaemia, lymphoma, colorectal, head and neck. Adalimumab is the therapy for the treatment of auto-immune disorders such as rheumatoid arthritis, psoriasis and inflammatory bowel disease. According to the terms of the agreement, Reliance Life Sciences will manufacture these products at its facility in Navi Mumbai and supply to Torrent Pharma for a period of 10 years, after obtaining all necessary regulatory approvals.
Torrent had launched exclusive divisions for oncology and dermatology segments in 2011-12. The licensing agreement with Reliance Life Sciences is expected to significantly boost its presence in these segments in the coming years, said a statement from Torrent.
Rituximab and Cetuximab cater to the oncology segment and are used in the treatment of various cancers such as leukaemia, lymphoma, colorectal, head and neck. Adalimumab is the therapy for the treatment of auto-immune disorders such as rheumatoid arthritis, psoriasis and inflammatory bowel disease. According to the terms of the agreement, Reliance Life Sciences will manufacture these products at its facility in Navi Mumbai and supply to Torrent Pharma for a period of 10 years, after obtaining all necessary regulatory approvals.
Torrent had launched exclusive divisions for oncology and dermatology segments in 2011-12. The licensing agreement with Reliance Life Sciences is expected to significantly boost its presence in these segments in the coming years, said a statement from Torrent.
